Novo Nordisk is an international pharmaceutical company headquartered in Denmark, with more than 90 years of experience in the innovation of solutions for the treatment of diabetes. Novo Nordisk is committed to research and development of treatments for hemophilia care, treatment with growth hormone and hormone replacement therapy.Novo Nordisk employs about 41,500 employees in 75 countries and is present with its products in more than 180 countries worldwide.
Novo Nordisk has Sales and Marketing operations in Italy, headquartered in Rome.
Contact
NOVO NORDISK SPA
Via Elio Vittorini, 129
00144 Rome (Italy)
Tel. +39 06.500881
Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently…
Novo Nordisk is one of the very few pharmaceutical multinationals that has such a strong focus on one therapeutic area. Although the company is now diversifying, diabetes remains its leading…
Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person…
Italy is a key destination for global clinical trial programs with EUR 700 million invested in 2020 alone according to national industry association Farmindustria, bringing access to medicines, knowledge, skills,…
In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader,…
Sanofi’s Country Lead, President & Managing Director for Italy Marcello Cattani discusses his career track and explains the company’s broad manufacturing footprint in the country – where Sanofi has four…
Luca Benatti, one of Italian biotech’s most notable entrepreneurs, outlines some of the key challenges of starting a biotech company in Europe, highlights how these barriers can be overcome, and…
Serial bioentrepreneur Luca Benatti introduces EryDel, an Italian firm based on the concept of using a patient’s red blood cells to deliver drugs. Benatti also weighs in on the strengths…
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over…
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and…
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
See our Cookie Privacy Policy Here
